Only 20 full-company mergers or acquisitions occurred throughout the year, although asset acquisition deals were more common.

The companies said they plan to explore a range of questions including the clinical implementation of the Alzheimer's disease biomarker phosphorylated tau 217.

Consolidation within the industry also remained brisk as cost and reimbursement concerns provided acquisition opportunities for large national outfits.

Last week, readers were most interested in Labcorp's acquisition of assets from MAWD, a CE mark for Roche's mass spec system, and features on Volition and Siemens Healthineers.

The agency made multiple decisions regarding coverage for diagnostic and laboratory testing that have affected the industry.

The company consolidated its instrument lineup with its newer Atellica instruments and is phasing out support for Advia and Dimension branded analyzers through 2030.

Under the agreement, Labcorp will manage Graves Gilbert's main full-service laboratory in Bowling Green, Kentucky and its facility in Glasgow, Kentucky.

Samples for the validation will be collected at the Catholic University of Korea and will represent people across all stages of Alzheimer's disease.

Labcorp will acquire portions of the lab's clinical and women's health testing businesses, while MAWD will continue to provide anatomic and other pathology services.

The deal for shares and cash is expected to close in the first half of 2025, and Sonic expects that it will be immediately accretive to earnings per share.

The Diagnostics Development Services program is, so far, being used to help point-of-care testing firm Fluxergy bring to market a test for sexually transmitted infections.

The US Centers for Disease Control and Prevention will support proof-of-concept development of primers and probes by Hologic for a laboratory-developed test.